Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered

• Arnault Tauziède-Espariat,
• David Castel,
• Yassine Ajlil,
• Lucie Auffret,
• Romain Appay,
• Cassandra Mariet,
• Lauren Hasty,
• Alice Métais,
• Fabrice Chrétien,
• Jacques Grill,
• Pascale Varlet

Affiliations

Arnault Tauziède-Espariat

GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital

David Castel

U981, Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy, Université Paris- Saclay

Yassine Ajlil

U981, Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy, Université Paris- Saclay

Lucie Auffret

U981, Molecular Predictors and New Targets in Oncology, INSERM, Gustave Roussy, Université Paris- Saclay

Romain Appay

Department of Pathology, APHM La Timone

Cassandra Mariet

GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital

Lauren Hasty

GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital

Alice Métais

GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital

Fabrice Chrétien

GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital

Jacques Grill

Paris University France

Pascale Varlet

GHU Paris Psychiatrie Neurosciences, Department of Neuropathology, Sainte-Anne Hospital